{
    "clinical_study": {
        "@rank": "11460", 
        "arm_group": [
            {
                "arm_group_label": "Empirical therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "selection of antibiotic according to medication history"
            }, 
            {
                "arm_group_label": "Genotypic resistance guided therapy", 
                "arm_group_type": "Experimental", 
                "description": "selection of antibiotics according to genotypic resistance"
            }
        ], 
        "brief_summary": {
            "textblock": "We aimed to compare the efficacy of genotypic resistance guided sequential therapy vs.\n      empiric therapy in the third line therapy. Factors affecting the eradication rates,\n      including the antibiotic resistance, CYP2C19 polymorphism, CagA and VacA status will also be\n      assessed."
        }, 
        "brief_title": "Genotypic Resistance Guided Therapy in Helicobacter Pylori Eradication", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Self Efficacy", 
        "detailed_description": {
            "textblock": "The primary aim of this study is to compare the regimens selected using either one of the\n      method (1) genotypic resistance guided versus (2) medication history guided therapy. (rather\n      than to compare the efficacy of any drugs)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged greater than 20 years who have persistent H. pylori infection after at\n             least two treatments and are willing to receive third line rescue regimens are\n             considered eligible for enrollment.\n\n        Exclusion Criteria:\n\n          -  Patients will be excluded from the study if any one of the following criteria is\n             present: (1) children and teenagers aged less than 20 years, (2) history of\n             gastrectomy, (3)gastric malignancy, including adenocarcinoma and lymphoma, (4)\n             previous allergic reaction to antibiotics (Amoxicillin, Klaricid, Cravit) and prompt\n             pump inhibitors (esomeprazole), (5)contraindication to treatment drugs, (6) pregnant\n             or lactating women, (7) severe concurrent disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01725906", 
            "org_study_id": "201202068MIC"
        }, 
        "intervention": [
            {
                "arm_group_label": "Empirical therapy", 
                "description": "Nexium  (esomeprazole), 40mg, bid, 14 days, plus\nAmoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus\nFlagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs\nSelect either one of the drugs according to medication history Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14", 
                "intervention_name": "empirical therapy", 
                "intervention_type": "Drug", 
                "other_name": "selection of antibiotics according to medication history"
            }, 
            {
                "arm_group_label": "Genotypic resistance guided therapy", 
                "description": "Nexium  (esomeprazole), 40mg, bid, 14 days, plus\nAmoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus\nFlagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs\nSelect either one of the drugs according to genotypic resistance results Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14", 
                "intervention_name": "Genotypic resistance guided therapy", 
                "intervention_type": "Drug", 
                "other_name": "selection of antibiotic according to genotypic resistance"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Antibiotics, Antitubercular"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "genotypic resistance guided therapy", 
        "lastchanged_date": "June 25, 2013", 
        "location": [
            {
                "contact": {
                    "email": "dtmed046@pchome.com.tw", 
                    "last_name": "Jyh-Ming Liou, MD", 
                    "phone": "+886972651883"
                }, 
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }, 
                    "name": "National Taiwan Universtiy Hospital"
                }, 
                "investigator": {
                    "last_name": "Ming-Shiang Wu, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yun-Lin County", 
                        "country": "Taiwan"
                    }, 
                    "name": "National Taiwan University Hospital, Yun-Lin Branch"
                }, 
                "investigator": {
                    "last_name": "Chieh-Chang Chen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Genotypic Resistance Guided Therapy in the Treatment of Helicobacter Pylori Infection", 
        "overall_contact": {
            "email": "dtmed046@pchome.com.tw", 
            "last_name": "Jyh-Ming Liou, MD", 
            "phone": "+886223123456", 
            "phone_ext": "63541"
        }, 
        "overall_official": {
            "affiliation": "National Taiwan University Hospital", 
            "last_name": "Jyh-Ming Liou", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary End Point: Eradication rate will be evaluated according to Intent-to-treat (ITT) and per-protocol (PP) analyses.\n(genotypic resistance versus empirical therapy) Urea breath test will be used to determine the eradication status", 
            "measure": "Eradication rate after third line rescue therapy", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01725906"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Taiwan University Hospital", 
            "investigator_full_name": "National Taiwan University Hospital", 
            "investigator_title": "Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "eradication rate in subgroup analysis according to antibiotic resistance and treatment regimen", 
            "measure": "eradication rates in subgroup analysis by antibiotic resistance and regimen", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "National Taiwan University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "National Science Council, Taiwan", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Taiwan University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}